Active	Status	Sponsor type	Region	Phase	Filter
4 Active 11 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Klimek, Ludger
PREPARED-1, NCT06339008: A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis	Recruiting	3	450	Europe, US, RoW	LY3650150, Placebo, Standard therapy for INCS	Eli Lilly and Company	Perennial Allergic Rhinitis (PAR)	10/25	02/27
ANCHOR-1, NCT05274750 / 2021-005037-16: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps Jul 2024 - Dec 2024 : Acceptance of regulatory submission in US for CRSwNP	Completed	3	276	Europe, Canada, Japan, US, RoW	Depemokimab (GSK3511294), Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Nasal Polyps	07/24	08/24
Pfaar, Oliver
PREPARED-1, NCT06339008: A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis	Recruiting	3	450	Europe, US, RoW	LY3650150, Placebo, Standard therapy for INCS	Eli Lilly and Company	Perennial Allergic Rhinitis (PAR)	10/25	02/27
ANCHOR-1, NCT05274750 / 2021-005037-16: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps Jul 2024 - Dec 2024 : Acceptance of regulatory submission in US for CRSwNP	Completed	3	276	Europe, Canada, Japan, US, RoW	Depemokimab (GSK3511294), Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Nasal Polyps	07/24	08/24